Home688235 • SHA
add
Beigene Ltd
Nakaraang pagsara
¥230.20
Sakop ng araw
¥214.55 - ¥231.37
Sakop ng taon
¥111.22 - ¥248.00
Market cap
185.35B CNY
Average na Volume
2.32M
P/E ratio
-
Dividend yield
-
Primary exchange
SHA
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.19B | 84.84% |
Gastos sa pagpapatakbo | 1.09B | 19.51% |
Net na kita | -139.70M | 58.27% |
Net profit margin | -11.75 | 77.43% |
Kita sa bawat share | -0.80 | -196.59% |
EBITDA | -33.25M | 90.73% |
Aktuwal na % ng binabayarang buwis | -112.84% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.63B | -17.16% |
Kabuuang asset | 5.92B | 1.99% |
Kabuuang sagutin | 2.59B | 14.14% |
Kabuuang equity | 3.33B | — |
Natitirang share | 106.72M | — |
Presyo para makapag-book | 7.37 | — |
Return on assets | -3.26% | — |
Return on capital | -4.29% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -139.70M | 58.27% |
Cash mula sa mga operasyon | 111.61M | 128.21% |
Cash mula sa pag-invest | -247.31M | 26.86% |
Cash mula sa financing | 30.05M | -92.11% |
Net change in cash | -155.64M | 57.59% |
Malayang cash flow | 434.97M | 505.95% |
Tungkol
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Itinatag
Okt 28, 2010
Website
Mga Empleyado
11,000
